MET Exon 14 Skipping Mutations: Essential Considerations for Current Management of Non–Small Cell Lung Cancer

Journal article

Open access

Peer reviewed

Kurtis D. Davies, Lauren L. Ritterhouse, Anthony N. Snow and Nikoletta Sidiropoulos

The Journal of molecular diagnostics : JMD, Vol.24(8), pp.841-843

05/09/2022

DOI: 10.1016/j.jmoldx.2022.04.005

Files and links (1)

url

https://doi.org/10.1016/j.jmoldx.2022.04.005View

Published (Version of record) Open Access

no abstract

Title: Subtitle: MET Exon 14 Skipping Mutations: Essential Considerations for Current Management of Non–Small Cell Lung Cancer
Creators: Kurtis D. Davies - Emerging and Evolving Biomarker Content Committee, A Working Group of the Training and Education Committee, Association for Molecular Pathology, Rockville, Maryland
Lauren L. Ritterhouse - Emerging and Evolving Biomarker Content Committee, A Working Group of the Training and Education Committee, Association for Molecular Pathology, Rockville, Maryland
Anthony N. Snow - Emerging and Evolving Biomarker Content Committee, A Working Group of the Training and Education Committee, Association for Molecular Pathology, Rockville, Maryland
Nikoletta Sidiropoulos - University of Vermont Medical Center
Resource Type: Journal article
Publication Details: The Journal of molecular diagnostics : JMD, Vol.24(8), pp.841-843
Publisher: Elsevier Inc
DOI: 10.1016/j.jmoldx.2022.04.005
ISSN: 1525-1578
eISSN: 1943-7811
Grant note: Bristol-Myers Squibb (https://doi.org/10.13039/100002491) Amgen (https://doi.org/10.13039/100002429) Loxo Oncology (https://doi.org/10.13039/100016936)
Language: English
Date published: 05/09/2022
Academic Unit: Pathology
Record Identifier: 9984258753202771

28 Record Views